

DAFTAR PUSTAKA

- Asgari, S. 2011. Role of micrnas in insect host-microorganism interactions. *Frontiers in Physiology* : 1–8.
- Ayaz, L., Cayan, F., Balci, S., Gorur, A., Akbayir, S., Yaroglu, H.Y., Unal, N.D., & Tamer, L. 2014. Circulating microRNA expression profiles in ovarian cancer. *Journal of Obstetrics and Gynecology* **2014**: 1-5.
- Bartel, D.P. 2004. MicroRNAs: genomic, biogenesis, mechanism, and function. *Cell* **116**: 281-297.
- Bast, R.C., Hennessy, B., & Mills, G.B. The biology of ovarian cancer: new opportunities for translation. *Nature Review Cancer* **9**: 415–428.
- Berek, J.S. & Bast, RC. 2006. Ovarian cancer, In: Cancer Medicine 7th ed.oleh Kufe, D.W., Bast, R.C., Hait, W.M. BC Decker, Inc., Hamilton: 1543-1568.
- Bhatt, A.N., Mathur, R., Farooque, A., Verma, A., & Dwarakanath, B.S. 2010. Cancer *biomarkers*-current perspectives. *Indian Journal of Medical Research* **132**: 129-149.
- Boeri, M., Verri, C., Conte, D., & Roz, L. 2011. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. *Proceeding of the National Academi of Sciences USA*, **108**: 3713–3718.
- Brian, K. 2010. *The complete guide to female fertility*, London: Hachette.
- Cao, J., Cai, J., & Huang, D. 2013. MiR-335 represents an invasion suppressor gene in ovarian cancer by targeting Bcl-w. *Oncology Reports* **30**: 701-706.
- Chan, K.Y.K., Ozcelik, H., Cheung, A.N.Y., Ngan, H.Y.S., & Khoo, U. 2002. Epigenetic factor controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. *Cancer research* **62**: 4151-4156.
- Chao A, Lai. C.H, Chen.H., Lin C.Y., Tsai C.L., Tang Y.H, Huang H.J., Lin C.T., Chen M.Y., Huang K.G., Chou H.H., Chang T.C., Chen S.J., &



- Wang T.H. 2014. Serum microRNAs in clear cell carcinoma of the ovary, *Taiwanese Journal of Obstetrics & Gynecology* **53**: 536-541.
- Cheng, H.H., Son Yi, H., Kim, Y., Kroh, E.M., Chien, J.W., M Eaton, K.D., Goodman, M.T., Trait, J.F., Tewari, M., & Pritchard, C.C. 2013. Plasma processing condition substantially influence circulating microRNA biomarker levels. *Plos one* **8**(6): e64795.
- Chugh, P. & Dittmer, D.P. 2012. Potential pitfalls in microRNA profiling. *WIREs RNA*: 1-6.
- Davidson, B. & Trope, C.G. 2014. Ovarian cancer: diagnostic, biological and prognostic, aspects. *Women Health* **10**(5): 519-33.
- Dileva, G., & Croce, C.M. 2013. The Role of microRNAs in the Tumorigenesis of Ovarian Cancer. *Frontiers in Oncology*. **3**: 153.
- Dong, Q., Meng, P., Wang, T., Qin, W., Qin, W., Wang, F., Yuan, J., Chen, Z., Yang, A., & Wang, H. 2010. *MicroRNA Let-7a Inhibits Proliferation of Human Prostate Cancer Cells In Vitro and In Vivo by Targeting E2F2 and CCND2*. *Plos One* **5**(4): e10147
- Dutta, S., Wang, F., Phalen, A., & Fishman, D.A. 2010. *Biomarkers for ovarian cancer detection and therapy*. *Cancer Biology & Therapy* **9**(9): 668-677.
- Engel, J., Eckel, R., Schubert-Fritschle, G., Kerr, J., Kuhn, W., Diebold, J., Kimming, R., Rchbock, J., & Holzel, D. 2002. Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. *European Journal of Cancer* **38**(2002): 2435-2445.
- Esquela-Kersher, A., & Slack, F.J. 2006. Oncomirs-microRNAs with a role in cancer. *Nature Review Cancer* **6**: 259-269.
- Falcone, G., Felsani, A., D'Agnano, I. 2015. Signaling by exosomal microRNA in cancer. *Journal of Experimental & Clinical Cancer Research* **34**.
- Fan, X., Liu, Y., & Jiang, J. 2010. miR-20a promotes proliferation and invasion by targeting APP in human ovarian cancer cells. *Acta Biochimica et Biophysica Sinica* **42**: 318-324



- Friendman, R.C., Farh, K.K.H., Burge, C.B., & Bartel, D.P. 2009. Most mammalian mRNAs are conserved targets of microRNAs. *Genome Research* **19**(1): 92-105.
- Genecard. 2017. MIR144 gene. <http://www.genecards.org/cgi-bin/carddisp.pl?gene=MIR144&keywords=MICRORNA-144-5p>. (diakses 18-06-2017; 10.53 WIB).
- Globocan. 2012. <<http://globocan.iarc.fr/Pages/online.aspx>>. (diakses 18-06-2017;10.50 WIB).
- Gu, Y., Zhang, M., Peng, F., Fang, L., Zhang, Y., & Liang, H. 2014. The BRCA1/2- directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2. *Oncotarget* **6**(4): 2397–406.
- Gubbels, J.A.A., Claussen, N., Kapur, A.K., Connor, J.P., & Patankar, M.S. 2010. The detection, treatment, and biology of epithelial ovarian cancer. *Journal of Ovarian Research* **3**: 1-11.
- Ha, M. & Kim, V.N. 2014. Regulation of microRNA biogenesis. *Nature Reviews Molecular Cell Biology* **15**(8): 509-524.
- Hamm, B. & Forstner, R., 2007, *MRI and CT of the female pelvic*, Berlin: Springer.
- Hansen, T.F., Christensen, R. dP., Andersen, R.F., Sorensen, F.B., Johnsson, A., & Jakobsen. 2013. MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Result from the Nordic ACT trial. *British Journal of Cancer* **109**: 1243-1251.
- Hata, A. & Kashima, R. 2016. Dysregulation of microRNA biogenesis machinery in cancer. *Critical Reviews in Biochemistry and Molecular Biology* **51** (3): 121-134.
- Hausler, S.F., Keller, A., Chandran, P.A., Ziegler, K., Zipp, K., & Heuer, S. 2010. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. *British Journal of Cancer* **103**: 693– 700.



- Hayes, J., Peruzzi, P.P., & Lawler, S. 2014. MicroRNAs in cancer: *biomarkers, functions and therapy. Trends in Molecular Medicine* **20**(8): 460-469.
- Holschneider, C.H. & Berek, J.S. 2000. Ovarian cancer: epidemiology, biology, and prognostic factors. *Seminars in Surgical Oncology* **19**: 3-10.
- Hull, M.L. & Nisenblatt, V. 2013. Tissue and circulating microRNA influence reproductive function in endometrial disease. *Reproductive Biomedicine Online* **27**: 515-529.
- Iorio, M.V., Visone, R., Di Leva, G., Donati, V., Petrocca, F., Cassalini, P., Taccioli, C., Volinia, S., Liu, C., Alder, H., Calin, G.A., Menard, S., & Croce, C.M. 2007. MicroRNA signatures in human ovarian cancer. *Cancer Research* **67**(18): 8699-8707.
- Iwagami, Y., Eghuci, H., Nagano, H., Akita, H., Hama, N., Wada, H., Kawamoto, K., Kobayashi, S., Tomokuni, A., Tomimaru, Y., Mori, M., & Doki, Y. 2013. MiR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1. *British Journal of Cancer* **109**: 501-511.
- Jayson, G., Kohn, E.C., Kitchener, H.C., & Lederman, J.A. 2014. Ovarian cancer. *Lancet* **384**: 1376-88.
- Jhamb, N. & Lambrou, N.C. 2010. Epidemiology and Clinical Presentation of Ovarian Cancer. *Elsevier*: 1-15.
- Kaku, T., Ogawa, S., Kawano, Y., Ohishi, Y., Kobayashi, H., Hirakawa, T., & Nakano, H. 2003. Histological classification of ovarian cancer. *Medical Electron Microscopy* **36**: 9-17.
- Kamaladewi. I. 2016. *Cara alami deteksi dini dan cegah 7 kanker pada wanita. Pena Cinta*, Jakarta.
- Kan, C.W., Hahn, M.A., Gard, G.B., Maidens, J., Huh, J.Y., & Marsh, D.J. 2012. Elevated Levels of Circulating MicroRNA-200 Family Members Correlate with Serous Epithelial Ovarian Cancer. *BMC Cancer* **12**: 627.
- Kinose, Y., Sawada, K., Nakamura, K., & Kimura, T. 2014. The Role of microRNA in Ovarian Cancer. *BioMed Research International* **2014**: 1-11.



- Kloosterman, W.P. & Plasterk, R.H. 2006. The diverse function of microRNAs in animal development and disease. *Developmental Cell* **11**: 441--450.
- Kroh, E.M., Parkin, R.K., Mitchell, P.S., & Tewari, M. 2010. Analysis of circulating microRNA biomarkers in plasma and serum quantitative reverse transcription-PCR (qRT-PCR). *Methods* **50**: 298-301.
- Kurian, A.W., Balise, R.R., McGuire, V., & Whittemore, A.S. 2004. Histologic types of epithelial ovarian cancer: have they different risk factors?. *Gynecologic Oncology* **96**(2005): 520-530.
- Laios, A., O'Toole, S., Flavin, R., Martin, C., Kelly, L., Ring, M., Finn, P.S., Barret, C., Loda, M., Gleeson, N., D'Arcy, T., McGuinness, E., Sheils, O., Sheppard, B., & O'Leary, J. 2008. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. *Molecular Cancer* **7**(35): 1-14.
- Landi, D., Gemignani, F., & Landi, S. 2012. Role of variations within microRNA-binding sites in cancer. *Mutagenesis* **27**(2): 205-210.
- Le, X, F., Merchant, O., Robert, C., Bast Jr., & Calin, G.A. 2010. The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade. *Cancer Microenvironment* **3**: 137-147
- Liang, S., He, L., Zhao, X., Miao, Y., Gu, Y., Guo, C., Xue, Z., Dou, W., Hu, F., Wu, K., Nie, Y., & Fan, D. 2011. MicroRNA Let-7f Inhibits Tumor Invasion and Metastasis by Targeting MYH9 in Human Gastric Cancer. *Plos One* **6**(4): e18409
- Lin, J. & Redies, C. 2012. Histological evidence: housekeeping genes beta-actin and GAPDH are of limited value for normalization of gene expression. *Development Genes & Evolution* **222**: 369-376.
- Lin, S., & Gregory, R. I., 2015, MicroRNA biogenesis pathways in cancer, *Nature Review Cancer* **15**(6): 321-333.
- Livak, K.J., & Schmittgen, T.D., 2001, Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the $2^{-\Delta\Delta CT}$ Method, *Methods* **25**: 402-408.
- Mader, S.S., 2006, *Human biology*, New York: McGraw-Hill Companies.



- Marchini, S., Cavaliere, D., Fruscio, R., Calura, E., Garavaglia, D., & Fusco N.I. 2011. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. *Lancet Oncology* **12**: 273–85.
- Matsushita, R., Seki, N., Chiyomaru, T., Inoguchi, S., Ishihara, T., Goto, Y., Nishikawa, R., Mataka, H., Tatarano, S., Itesako, T., Nakagawa, M., & Enokida, H. 2015. Tumour-suppressive microRNA-144-5p directly targets CCNE1/2 as potential prognostic marker in bladder cancer. *British Journal of Cancer* **113**: 282-289.
- Meng, F., Henson, R., Wehbe-Janek, H., Ghosal, K., Jacob, S.T., & Patel, T., 2007, MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer, *Gastroenterology* **133**: 647-658.
- Meurer, S., Kruger, K., & Mooren, F.C. 2016. MicroRNA and exercise. *Dtsch Z Sportmed* **67**: 27-34.
- Mirtarbase, 2015, < <http://mirtarbase.mbc.nctu.edu.tw/>> (diakses 25-07-2016; 20:31 WIB).
- Moya-Moreno, J.M., Vilella, F., & Simon, C. 2013. MicroRNA: key gene expression regulators. *Fertility and Sterility*: 0015-0282.
- Nam, E., Yoon, H., Kim, S.W., Kim, H., Kim, Y.T., Kim, J.H., Kim, J.W., & Kim, S. 2008. MicroRNA expression profiles in serous ovarian carcinoma. *Clinal Cancer Research* **14**(9): 2690-2695.
- NCBI. 2017. MicroRNA-320c-1[Homo sapiens(human)]. <https://www.ncbi.nlm.nih.gov/gene/100302135>. (diakses 23-05-2017; 13:57 WIB).
- Olson, P., Lu, J., Zhang, H., Shai, A., Chun, M., Wang, Y., Libutti, S.K., Nakakura, E.K., Golub, T.,R., & Hanahan, D. 2009. MicroRNA dynamics in the stage of tumorigenesis correlate with hallmark capabilities of cancer. *Genes & Development* **23**: 2152-2165.
- Pan, H., Wen, Z., Huang, Y., Cheng, X., Wang, G., Zhou, Y., Wang, Z., Guo, Y., Cao, Y., & Zhou, G. 2015. Down-regulation of microRNA-144 in air pollution-related lung. *Nature: Scientific Report* **5**: 1-11.



- Prat, J. 2015. FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. *Journal of Gynecologic Oncology* **26** (2): 87-89.
- Reboucas, E., Costa, J.J., Passos, M.J., Passos, J.R., van den Hurk, R., & Silva, J.R.V. 2013. Real time PCR and importance of housekeeping genes for normalization and quantification of mRNA expression in different tissues. *Brazilian Archives of Biology and Technology* **56**(1): 143-154.
- Resnick, K.E., Alder, H., Hagan, J.P., Richardson, D.L., Croce, C.M., & Cohn, D.E. 2009. The Detection of Differentially Expressed MicroRNAs from The Serum of Ovarian Cancer Patients Using a Novel Real-Time PCR Platform, *Gynecology Oncology* **11**: 55-59.
- Ruddon, R.W. 2007. *Cancer Biology*; 4th ed. Oxford University Press, New York: 530 hlm.
- Samuel, M.C., Kwong, J., Welch, W.R., Samimi, G., Ozbun, L., Bonome, T., Birrer, M.J., Berkowitz, R.S., & Wong, K. 2007. Etiology and pathogenesis of epithelial ovarian cancer. *Disease Markers* **23**(5-6): 367-376.
- Schwazenbach, N., Nishida, N., Calin, G.A., & Pantel, K. 2014. Clinical relevance of circulating cell-free microRNAs in cancer. *Nature Review Clinical Oncology* **11**: 145-56.
- Slaus-Pecina, N. 2003. Tumor suppressor gene E-cadherin and its role in normal and malignant cells. *Cancer Cell International* **3**(17): 1-7.
- Stenvang, J., Petri, A., Lindow, M., Obat, S., & Kauppinen, S. 2013. Inhibition of microRNA function by anti-miR oligonucleotides. *Silence* **3**: 1-17.
- Sui, C., Meng, F., Li, Y., & Jiang, Y. 2015. *miR-148b* Reverses Cisplatin-Resistance in Non-Small Cell Cancer Cells Via Negatively Regulating DNA (cytosine-5)-Methyltransferase 1(DNMT1) Expression. *Journal of Translational Medicine* **13**: 132.
- Taylor, D.D. & Taylor-Gercel, C. 2008. MicroRNA signatures of tumor-derived exosome as diagnostic biomarkers of ovarian cancer. *Gynecologic Oncology* **110**: 13-21.



- Taylor, M.A. 2015. Circulating microRNAs as *biomarkers* and mediators of cell-cell communication in cancer. *Biomedicines* **3**: 270-280.
- Vishnubalaji, R., Hamam, R., Yue, S., Al-Obeed, O., Kassem, M., Liu, F., Aldahmash, A., & Alajez, N.M. 2016. MicroRNA-320 suppresses colorectal cancer by targeting SOX4, FOXM1, and FOXQ1. *Oncotarget* **7**(24): 35789-35802.
- Wang, J., Zhang, K.Y., Liu, S.M., & Sen, S. 2014. Tumor-Associated Circulating MicroRNAs as *Biomarkers* of Cancer. Review. *Molecules* **19**: 1912-1938.
- Wang, K., Yuan, Y., Cho, J., McClarty, S., Baxter, D., & Galas, D. 2012. Comparing the microRNA spectrum between serum and plasma. *PLOS ONE* **7**(2): 1-9.
- Wang, X., Wu, J., Lin, Y., Zhu, Y., Xu, X., Liang, Z., Li, S., Hu, Z., Zheng, X., & Xie, L. 2014. MicroRNA-320c inhibits tumorous behavior of bladder cancer by targeting cyclin-dependent kinase 6. *Journal of Experimental & Clinical Cancer Research* **33**: 57-69.
- Wu, R.L., Ali, S., & Bandyopadhyay, S. 2015. Comparative Analysis of Differentially Expressed miRNAs and their Downstream mRNAs in Ovarian Cancer and its Associated Endometriosis. *Journal of Cancer Science & Therapy* **7**(7): 258-265.
- Xia, M.P.H. 2008. Great Potential of MicroRNA in Cancer Stem Cell. Review Article. *Journal of Cancer Molecules* **4**(3): 79-89.
- Yao, J., Liang, L., Zhang, Y., Ding, J., Tian, Q., Li, J., & He, X. 2012. GNAI1 suppresses tumor cell migration and invasion and is post transcriptionally regulated by miR-320a/c/d in hepatocellular carcinoma. *Cancer Biology & Medicine* **9**: 234-241.
- Zaman, M.S., Maher, D.M., Khan, S., Jaggi, M., & Chauhan, S.C. 2012. Current Status and Implications of MicroRNAs in Ovarian Cancer Diagnosis and Therapy. *Journal of Ovarian Research* **5**: 44.
- Zhang, H. Zuo, Z., Lu, X., Wang, L., Wang, H., & Zhu Z., 2012, MiR-25



regulates apoptosis by targeting Bim in human ovarian cancer, *Oncology Report* **27**: 594-598.

Zhang, J., Li, S., Li, L., L, M., Guo, C., Yao, J., & Mi, S. 2015. Exosome and exosomal microRNA: trafficking, shorting, and function. *Genomic Proteomic Bioinformatics* **13**: 17-24.

Zhang, L., Volinia, S., Bonome, T., Calin, G.A., Greshock, J., Yang, N., Liu, C., Giannakakis, A., Alexiou, P., Hasegawa, K., Johnstone, C.N., Megraw, M.S., Adam, S., Lassus, H., Huang, J., Kaur, S., Liang, S., Sethupathy, P., Leminen, A., Simossis, V.A., Sandaltzopoulos, R., Naomoto, Y., Katsaros, D., Gimotty, P.A., DeMichele, A., Huang, Q., Butzow, R., Rustgi, A.K., Weber, B.L., Birrer, M.J., Hatzigeorgiou, A.G., Croce, C.M., & Coukos, G. 2008. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. *PNAS* **105** (19): 7004-7009.

Zheng H., Liu J.Y., Song F.J., & Chen K.X. 2013. Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer. *Review. Cancer Biology & Medicine* **10**: 123-130.